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Intro 
lncretin hormones, such as gastric inhibitory peptide and glucagon-like 
peptide-1 (GLP-1 ), are produced in the intestines, and their combined ef-
fects are known as the incretin effect.1 Glucagon-like peptide 1 (GLP-1) 
stimulates glucose-dependent insulin secretion, inhibits postprandial 
glucagon secretion, and slows gastric emptying, thus reducing appetite. 
Endogenous GLP-1 is degraded rapidly by the enzyme dipeptidyl pepti-
dase-4 (DPP-4), resulting in an extremely short half-life. Newer treat-
ments, such as exenatide, liraglutide and exenatide long-acting release 
(LAR), have been developed as medications that exert GLP-1 activity 
and yet resist DPP-4 inactivation. Exenatide was approved by the FDA 
in 2005 as an adjunct therapy for type 2 diabetes mellitus (T2DM). It 
was the first incretin mimetic to demonstrate a decrease in hemoglobin 
A
1
C (HbA10) via glycemic control (average 1 percent reduction) and a 
significant decrease in body weight (1 .6 - 5.3 kg reduction).2•3 Liraglutide 
is the newest GLP-1 mimetic to be approved for T2DM, gaining approval 
in early 2010.1 Unlike exenatide, which needs to be dosed twice daily, 
liraglutide is designed for once-daily dosing. A long-acting exenatide 
product, Bydureon® (exenatide LAR), is currently being developed 
for once-weekly dosing. With the recent approval of liraglutide and the 
possable approval of exenatide LAR, practitioners may find it valuable to 
assess how each GLP-1 agent will fit into therapy for T2DM. 
Exenatide 
The use of exenatide has widely been compared to the use of long-act-
ing insulin for T2DM that is uncontrolled after initial therapies. Although 
long-acting insulin may offer a greater decrease in HbA10 than exenatide, 
it causes weight gain, an unwanted effect in T2DM patients.4 Over the 
past five years, exenatide has established a role within T2DM therapy, 
but long-term adverse events have also been noted with therapy. 
Like other new treatments for T2DM, the adverse drug reaction (ADR) 
profile of exenatide has been a cause for concern as long-term treat-
ment data becomes available. The most common ADRs associated with 
exenatide treatment are nausea, vomiting, diarrhea and hypoglycemia.5 
However, most of these ADRs occur in combination therapy with other 
T2DM medications and can be controlled through monitoring therapy. 5 
In addition to minor adverse reactions with exenatide, as of Jan. 1, 2010, 
the FDA has received 36 post-marketing reports of acute pancreatitis, 
including six cases of hemorrhagic or necrotizing pancreatitis and two 
deaths. 2 However, it is important to note that 90 percent of these pa-
tients had confounding factors for pancreatitis (obesity, hyperlipidemia, 
hypertriglyceridemia, alcohol use). 
Thirty additional cases were subsequently reviewed by the FDA, none 
of which resulted in fatality. Initial symptoms began at an average of 34 
days after starting exenatide treatment, and abdominal pain was the most 
common symptom, occurring in 23 of the 30 patients. Symptoms subsided 
for 22 of the 23 patients after exenatide was discontinued; however, re-
exposure caused a recurrence of symptoms in most patients. 
Because of the controversy regarding the issue of pancreatitis with the use 
of exenatide, the manufacturer has recently made an addition to the pack-
age insert pertaining to patient monitoring.6 The warning recognizes that 
patients should be monitored for symptoms of pancreatitis when treatment 
is started on the medication or if the dose is increased. If symptoms are 
consistent for diagnosis of pancreatitis, treatment should be discontinued 
immediately and the patient should be appropriately managed. These 
patients are then ineligible for any future treatment with exenatide. 
The FDA also has received 78 cases of altered renal function in patients 
receiving exenatide treatment (62 acute, 16 renal insufficiency).7 
Initial symptoms occurred three days to two years after initiation of 
exenatide treatment in patients who were 23-83 years old. Fourteen of 
these patients had a past medical history of chronic kidney disease, a 
contraindication for exenatide treatment, and 95 percent had at least 
one risk factor for altered kidney function, such as cardiac insufficiency, 
hypertension, pancreatitis, rhabdomyolysis or urinary tract infection. 
Several patients were also at increased risk due to the use of antiretrovi-
rals, antihypertensives, diuretics or NSAIDs. Four deaths were reported, 
and 91 percent of the treated patients required hospitalization. Symp-
toms improved in half of the patients after discontinuation of exenatide, 
while 18 patients required dialysis and two required a renal transplant. 
A precautionary statement has since been added to the labeling for 
exenatide about treatment in patients with low creatinine clearance 
(<50 mUmin).5 Practitioners should continue to evaluate renal function 
prior to exenatide treatment and throughout the progression of T2DM in 
individual patients. 
In late 2009, the FDA granted approval to use exenatide monotherapy 
in T2DM patients. The indication was granted after a study showed 
improved glucose control and weight loss in a 24-week, randomized, 
double-blind, placebo-controlled trial with 203 patients completing 
the study. 8 Patients were randomized to 5 mcg twice-daily or 1 o mcg 
twice-daily dosing, with the primary endpoint of decreased HbA
10 
and 
secondary endpoints of fasting serum glucose, postprandial glucose and 
weight. Results from the study showed a statistically significant decrease 
in mean postprandial glucose (5 mcg-17.5mg/dl;10 mcg-18.7 mg/dl; 
placebo -5.2 mg/dl; p <0.001). Adverse events were similar between 
monotherapy and adjunct therapy, with nausea being the most common. 
The effectiveness of monotherapy compared to adjunct therapy has not 
yet been studied. 
Exenatide Long-acting Release (LAR) 
Amylin Pharmaceuticals, Eli Lilly, and Alkermes have developed a 
long-acting exenatide product, Bydureon® (exenatide LAR), which is a 
once-weekly form of Byetta. Recently, the FDA denied approval due to 
clarifications needed on labeling, risk evaluation and mitigation strategy 
(REMS), and the manufacturing process. At the time this article was writ-
ten, Bydureon was still not FDA-approved, but the following two studies 
demonstrate its potential in the treatment of T2DM. 
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A 30-week, randomized, non-inferiority, comparator-controlled, open-label 
trial was performed comparing exenatide LAR 2 mg once-weekly to 1 O mcg 
exenatide twice-daily to assess safety, efficacy, tolerability and non-inferior-
ity of the long-acting product. This product was considered to be non-infe-
rior tt HbA
10 
change was <0.4 percent at week 30. A total of 295 weight-
stable patients with T2DM were included in this study. Subjects were either 
naive to anti-diabetic treatment or were receiving one or more anti-diabetic 
agents, including metformin, sulfonylureas, thiazolidinediones or a combi-
nation, for at least two months prior to the trial. Patients were randomized 
into two groups, both receiving 5 mcg exenatide twice daily for three days, 
then either 2 mg exenatide LAR for 30 weeks or 5 mcg exenatide twice 
daily for 28 days followed by 1 O mcg exenatide for the remainder of the 30-
week study. Results showed that, by week 10, the once-weekly group had 
a signtticant decrease in HbA
10
, 1.9, compared to the twice-daily group, 1.5 
(p=0.0023) despite patient background. The once-weekly group also had 
77 percent of patients achieve HbA10 of '5.7 percent compared to 61 percent 
in the twice-daily group (p=0.0039). The twice-daily group had 35 percent 
of patients with a baseline HbA
10 
of ~9 percent achieve a final HbA 1 c of !.7 
percent, while the once-weekly group had 65 percent of patients achieve 
this level (p=0.02). Bodyweight decreased in both the exenatide and 
exenatide LAR groups (-3.6 kg and-3.7 kg, respectively, p=0.89). Fasting 
plasma glucose levels signtticantly decreased in the once-weekly group 
versus the twice-daily group (-41.4 mg/dl and -25.2 mg/dl), respectively, 
p<0.0001). In addition, the Diabetes Treatment Satisfaction Questionnaire 
(DTSQ) showed a significant increase in satisfaction in the once-weekly 
group. Adverse events for the once-weekly group were mild and included 
nausea (26.4 percent) and injection site pruritus (17.6 percent) and were 
significantly lower than the twice-daily group. No major hypoglycemic 
events, occurrences of pancreatltis or significant abnormalities were found. 
Overall, both exenatide and exenatide LAR decreased HbA10• Significant 
reduction in HbA
10 
values due to continuous exposure to exenatide indicate 
that glycemic control provided by the once-weekly formulation is not inferior 
to the twice-daily formulation.12 
A 52-week, randomized, multi-center, open-labeled trial was performed to 
evaluate the effects of exenatide twice daily and exenatide once weekly on 
treatment satisfaction and quality of life. Patient-reported outcome instru-
ments included DTSQ and the Impact of Weight on Quality Of Ltte (IWOOL-
Lite), which were given at baseline and weeks 30 and 52. A total of 295 
patients were included - 148 in the 2 mg exenatide once-weekly and 14 7 in 
the 1 O mcg twice-daily during weeks 1-30, then 2 mg weekly for weeks 30-52. 
Results of the DTSQ scores showed that at week 52, treatment satisfaction 
improved in the once-weekly group. However, the IWQOL-Lite showed a 
signtticant increase in satisfaction in both groups (P<0.001), but there was no 
difference between them. After the twice-daily group switched to once-weekly 
exenatide, improvement was seen for treatment satisfaction, convenience, 
flexibility and continuance. In this group, the IWQOL-Llte also showed 
significant improvement in physical function and public distress. Overall, the 
weekly group had improved satisfaction with treatment convenience, flexibility 
and public distress. All comparisons were shown to be statistically significant 
with p<0.05. In addition, there was no difference in adverse events between 
the groups. Overall, the once-weekly form had improvement in satisfaction, 
convenience and flexibility. This could be a result of ease of use, less frequent 
administration, and greater improvement in glucose control with perceived 
hyperglycemia. The willingness to continue treatment could possibly improve 
adherence and, thus, the outcome and control of T2DM.13 
Liraglutide 
Recently approved by the FDA, liraglutide is authorized for use in T2DM 
as monotherapy or in combination with other anti-diabetic medications, 
such as metformin, thiazolidinediones or sulfonylureas.1 The approval was 
delayed due to possible risk of medullary thyroid cancer, though malignant 
tumors were only evident in animal trials. Novo Nordisk, the manufacturer 
of liraglutide, funded the Liraglutide Effect and Action in Diabetes (LEAD 
1-6) studies to establish the safety and efficacy of liraglutide. LEAD trials 
1, 2, 4 and 5 primarily focused on combination therapy with liraglutide and 
one or more oral antidiabetic medication, whereas LEAD-3 focused on 
monotherapy, and LEAD-6 compared liraglutide with exenatide. 
The LEAD-3 trial is a double-blinded, randomized trial performed to evalu-
ate and compare the efficacy of liraglutide 1.2 mg and 1.8 mg once daily 
with oral glimepiride 8 mg once daily as monotherapy for T2DM.9 A total 
of 746 participants with early T2DM were enrolled for the 52-week trial. 
Participants were 18-80 years old, had an HbA10 between 7-11 percent, 
had a BMI of !.40 kg/m2, and had not used insulin or corticosteroids in the 
previous three months. Participants were placed into one of three treat-
ment groups: 1.2 mg liraglutide (n=251 ), 1.8 mg liraglutide (n=247), or 8 
mg glimepiride (n=248). At the completion of the trial, HbA
10 
was reduced 
more significantly in both liraglutide therapies than glimepiride (Table 
1 ). Greater decreases in HbA10 were seen in patients previously treated 
with lifestyle modifications only as compared to those patients who had 
received oral anti-diabetic medications preceding the trial. Significantly 
more patients achieved the American Diabetes Association HbA10 target of 
less than 7 percent in the liraglutide therapies as compared to glimepiride 
(table 1). No major hypoglycemia occurred, though minor hypoglycemia 
occurred in all three groups. Nausea was more prevalent in liraglutide 
groups but decreased after four weeks. The LEAD-3 trial was extended 
another 52 weeks with 440 patients entering the extra year of treatment.10 
After the extension period was completed, mean reductions in HbA
10 
and 
those reaching the target goal were significantly greater with liraglutide 
1.2 mg and 1.8 mg than glimepiride (table 1 ). Treatment with liraglutide is 
shown to be effective and safe as monotherapy and produces significant 
greater reductions in HbA10 and FPG as compared with glimepiride. 
The LEAD-6 trial is a 26-week randomized trial that compares the safety 
and efficacy of liraglutide with exenatide in T2DM patients not adequately 
controlled on metformin alone (n=127), a sulfonylurea alone (n=45), or 
metformin plus a sulfonylurea (n=292}.11 The464 participants were 18-80 
years old, HbA10 between 7-11 percent, had a BMI of ~45 kg/m
2
, and had 
no previous insulin or exenatide. The patients continued on their treatment 
and were randomly chosen to receive either 1.8 mg liraglutide once daily 
(n=233) or 10 mcg exenatide twice daily (n=231). After 26 weeks, more 
patients reached target HbA
10 
levels of <7 percent and had significantly 
improved glycemic control with liraglutide than exenatide (table 1). Both 
liraglutide and exenatide groups had similar weight reductions (table 1 ). 
The incidence of nausea was initially similar in both groups but was less 
persistent in the liraglutide group (p<0.0001). Treatment satisfaction was 
measured using the Diabetes Treatment Satisfaction Questionnaire. Over-
all, treatment satisfaction was significantly better with liraglutide (n=161) 
than with exenatide (n=143) (p=0.0004). 
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Table 1. Efficacy of liraglutide (LIRA} as monotherapy in the treatment of T2DM. Results from two LEAD trials. LEAD-3 compared 
LIRA against glimepiride (GLIM} for efficacy as monotherapy. LEAD-6 compared the efficacy of LIRA to exenatide (EXEN}.9• 1°· 11 
Study Therapy No.of Mean HbAlc (%) 
pts 
Baseline Change 
LIRA 1.2mg 251 8.3 -0.84 
LEAD-3 LIRA 1.8mg 247 8.3 -1.14 
(Mono) GLIM 8mg 248 8.4 -0.51 
LEAD-3 URA l.2mg 149 8.1 -1.1 
(Mono LIRA 1.8mg 154 8.1 -1.4 
extension) GLIM 8mg 137 8.0 -0.6 
LEAD-6 LIRA l.8mg 233 8.2 -1.12 
(Vs. EXEN) EXEN lOmcg 231 8.1 -0.79 
*Baseline data not provided 
Conclusion 
New incretin based therapies have the possibility to influence the treat-
ment of T2DM. Exenatide, liraglutide and exenatide LAR appear to be 
relevant to the treatment of T2DM in their ability to decrease HbA,c while 
reducing weight and may be appropriate as monotherapy agents for 
some patients. Studies show that each agent exhibits a mild safety pro-
file with modest differences in therapeutic outcomes. Currently, patient 
preference and dosing schedule should be considered by the practi-
tioner when determining the preferred agent for the patient. Additional 
head-to-head trials may be beneficial to adequately compare exenatide, 
liraglutide, or exenatide LAR to further determine the specific role in 
therapy for each agent. 
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